Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The debt to assets ratio is N/A as of Tuesday, October 6, 2026.
DEBT TO ASSETS RATIO
N/A
Latigo Biotherapeutics Inc.
Market Cap
$1.01B
Debt to Assets Ratio
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO |
|---|---|---|
| Latigo Biotherapeutics Inc. (LTGO) | $1.01B | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $1.01B | 0.01% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.02B | 0.57% |
| Immatics N.V. (IMTX)vs › | $1.02B | 0.03% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.03B | 0.54% |
| MeiraGTx Holdings plc (MGTX)vs › | $998.37M | 0.28% |
| Aktis Oncology, Inc. (AKTS)vs › | $994.66M | 0.02% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.04B | 0.02% |
| Pacira BioSciences, Inc. (PCRX)vs › | $981.41M | 0.33% |
| Castle Biosciences, Inc. (CSTL)vs › | $1.05B | 0.07% |
Debt/Assets
N/A
Debt/Equity
N/A
Current Ratio
N/A
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
